Tempus Expands Immuno-Oncology Portfolio With The Launch Of AI-Enabled, Multimodal Immune Profile Algorithmic Tests For Research Use Only
Portfolio Pulse from Benzinga Newsdesk
Tempus AI, Inc. (NASDAQ:TEM) has launched its multimodal immune profile score (IPS) algorithmic test for research use only, marking the first offering in its expanding immunotherapy-based portfolio. Tempus is also collaborating with partners like Cleveland Clinic to develop additional algorithmic tests.
July 16, 2024 | 1:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tempus AI has introduced its multimodal immune profile score (IPS) algorithmic test for research use only, which is the first in its new immunotherapy-based portfolio. The company is also collaborating with Cleveland Clinic to develop more algorithmic tests.
The launch of the IPS algorithmic test and the collaboration with Cleveland Clinic are significant steps for Tempus AI, indicating growth in its product offerings and potential market expansion in the immuno-oncology space. This is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100